Intellia Therapeutics (NTLA) Misses Q2 EPS by 38c

Intellia Therapeutics (NASDAQ: NTLA) reported Q2 EPS of ($1.01), $0.38 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $6.6 million versus the consensus estimate of $11.89 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• L3Harris Technologies (LHX) Tops Q1 EPS by 15c; raises guidance
• ResMed (RMD) Tops Q3 EPS by 20c